ViroBlogy

See on Scoop.it – Virology News

“In the third quarter of 2012, we announced that we had successfully produced significantly more than 10 million doses of H1N1 influenza VLP vaccine at our commercial-scale facility in North Carolina and completed the DARPA project. In addition, we announced FDA authorization to initiate a Phase I clinical trial with IDRI for an H5N1 VLP vaccine to explore the possibility of enhanced protection with one dose of vaccine, continued development of the quadrivalent seasonal flu vaccine, and signed a commercial agreement with Philip Morris Products for influenza vaccines in China,” said Andy Sheldon, President and Chief Executive Officer of Medicago. “In 2013, we expect to see results from at least three clinical trials, which would reinforce our position with governments and companies to secure revenues and grant opportunities.”

Read more here: http://www.sacbee.com/2012/11/09/4974415/medicago-announces-2012-third.html#storylink=cpy

Still Going Green: the sensible thing to do.

See on www.sacbee.com

This entry was posted on 10 November, 2012 at 15:44 and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.